Dr Peter McCullough: Prescription and Over-the-Counter Treatments for Long COVID Syndrome (2023)
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
Over three years into the pandemic with nearly the entire country having become
sick with SARS-CoV-2, a virus engineered to invade the body, there are millions
suffering with long-hauler syndrome. Approximately half of patients admitted to
the ICU with COVID-19 will have post-COVID syndrome which is now understood to
be due to persistence of the SARS-CoV-2 Spike protein within cells, tissues, and
organs. Those vaccinated have been additionally loaded with Spike, so may have
even a worse course with prolonged symptoms including fatigue, lethargy, brain
fog, muscle loss, skin and hair changes, sleeplessness, and effort intolerance.
The magnitude of the problem has driven an all-encompassing search for
management strategies to resolve the syndrome(s).
Hope is on the
horizon with a preprint paper published by Halma et al summarizing the
prescription drug and over-the-counter candidates for therapy. In my practice, I
stylize the approach based on the patient and how recent the COVID-19 infection
was in their history. If there are lingering signs of infection, then a course
of full dose ivermectin can be considered. Aspirin is reasonable given increased
rates of heart attack and stroke after the illness. I have found the colchicine
appears to have an important role in pleurodynia or chest wall discomfort.
Additionally it is used with corticosteroids in vaccine-induced myopericarditis.
Low-dose naltrexone has been reported to ameliorate fatigue and inanition.
Metformin has supportive data and would be appropriate in pre-diabetes and those
with diabetes mellitus.
Halma, M.T.; Plothe, C.; Lawrie, T. Strategies for the
Management of Spike Protein-Related Pathology. Preprints 2023,
2023030344. https://doi.org/10.20944/preprints202303.0344.v1.
From the OTC list, I have found nattokinase, the Japanese product derived
from natto (a traditionalJapanese food made from whole soybeans that have been fermented with Bacillus subtilis var. natto.) to be the most compelling and scientifically supported approach to
clear Spike protein out of the body via proteolytic degradation. A host of
cellular protective, anti-oxidant approaches are listed with vitamin C and
NAC being readily available and widely used.
Nattokinase and Spike Protein
Tanikawa et al. examined the effect of nattokinase on the spike protein of SARS-CoV-2. In
the first experiment, they demonstrated that spike was degraded in a time
and dose-dependent manner in a cell lysate preparation that could be
analogous to a vaccine recipient. The second experiment demonstrated that
nattokinase degraded the spike protein in SARS-CoV-2 infected cells. This
was reproduced in a similar study done by Oba and colleagues in 2021.
Tanikawa T, Kiba Y, Yu J, Hsu K, Chen S, Ishii A, Yokogawa T, Suzuki R,
Inoue Y, Kitamura M. Degradative Effect of Nattokinase on Spike Protein of
SARS-CoV-2. Molecules. 2022 Aug 24;27(17):5405. doi:
10.3390/molecules27175405. PMID: 36080170; PMCID: PMC9458005.
Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary
according to purity. Kurosawa and colleagues have shown in humans that after
a single oral dose of 2000 FU D-dimer concentrations at six, and
eight hours, and blood fibrin/fibrinogen degradation products at four hours
after administration elevated significantly (p < 0.05, respectively).
Thus
an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic
and pharmacodynamic studies have not been completed, but several years of
market use as an over-the-counter supplement suggests nattokinase is safe
with the main caveat being excessive bleeding and cautions with concurrent
antiplatelet and anticoagulant drugs.
Ivermectin and Spike Protein
Former NIH researcher David Scheim, PhD, early in the pandemic proposed that
SARS-CoV-2 Spike protein was acting like a grappling hook pulling together
circulating red blood cells (RBSc) into long chains and clumps in a process
called hemagglutination (HA). This explained why the red blood cells could
not carry oxygen normally and was congruent with the finding of micro blood
clots in the lungs. Recently, Boschi et al have provided additional support
for this mechanism (source).
According to the authors: “Ivermectin blocked HA when
added to RBCs prior to spike protein and reversed HA when added
afterwards.”
In another spectacular publication, Stone et al,
describes the prompt improvement of oxygenation in patients with ivermectin
(source).
The published oxygenation curves from multiple studies clearly
show this physiological effect of ivermectin occurs so rapidly, it must be
explained by a direct anti-Spike protein effect of ivermectin. An
anonymous video of a critically ill man
demonstrates the very effect that Scheim, Stone, Hazan, and Babalola have
described in the Figure above. So for the next critically ill patient with
COVID-19, if the opportunity presents itself, push for the administration of
ivermectin. This is the only published therapy for COVID-19 that improves
oxygen saturation while the patient mounts a recovery. As in this man, it
may be the critical factor for a turnaround and a chance to walk out of the
hospital.
Key Takeaway
Patients should push their doctors to refer them to clinical trials, and
when that is not feasible, then empiric therapy can be pursued. It is
important to realize that in the absence of completed large randomized
placebo controlled randomized trials, which are easily 5 or more years away
in the future, no therapeutic claims can be made. In the meantime we must be
perceptive as patients and open-minded as clinicians to come up with
reasonable approaches that can be used to help those sick now with
post-COVID syndromes.
Though there are many long haulers treatment protocols out there, we
consider and recommend the I-Recover protocol as one of the best.
Given the lack of clinical trials of long-haul COVID-19 syndrome,
these recommendations are based on the abnormal changes within the
body associated with the COVID-19 disease and post viral illnesses
along with the collective experience of FLCCC members.
This protocol has also been used to treat post-vaccine inflammatory
syndromes with similar success. As with all FLCCC Alliance protocols,
the components, doses, and durations will evolve as more clinical data
accumulates.
Due to the marked overlap between long COVID and post-vaccine syndrome,
please refer to the I-RECOVER Post-Vaccine Treatment protocol for detailed treatment strategies.
The Wellness Company's acclaimed Spike Support Formula contains scientifically-researched
ingredients, including nattokinase, black seed oil, green tea extract
and selenium.
These ingredients are known for their ability
to dissolve spike protein, prevent it from binding to cells, and
repair tissue.
Recommended to maintain daily health for
anyone exposed to COVID, vaccines, or shedding – and may help your
body repair itself and remain at optimal health.
Where to buy Spike Support Formula: Spike Support Formula is available on The Wellness
Company's website. Here is the link: Spike Support Formula (Long Haul Formula)
Note: To get 10% OFF, please use this coupon code: ONEDAYMD
With the Federal Reserve initiating its rate-cutting cycle on September 17, 2025, by lowering rates by 25 basis points, markets are shifting toward sectors sensitive to lower borrowing costs, such as technology, real estate, small caps, and consumer discretionary. This environment favors growth-oriented assets and those with floating-rate debt exposure. Based on recent analyses from financial experts, we've compiled a forward-looking list of 10 recommendations (a mix of 10 stocks and 10 ETFs) expected to benefit from these dynamics through the end of September and into Q4. Selections prioritize high-conviction picks with strong upside potential, momentum, and sector tailwinds. Update: Top 10 Stocks and ETFs Poised to Outperform in October 2025 Below, we've incorporated recent performance data (YTD) for context on their trajectory. Top 10 Stocks to Watch in September 2025 These stocks have shown strong year-to-date performance in 2025, indicating potential to continue outperform...
The semiconductor industry remains a pivotal engine of global technological advancement, powering everything from smartphones and electric vehicles to cutting-edge AI and cloud computing infrastructure. For investors seeking to gain diversified exposure to this booming sector, semiconductor and AI-themed exchange-traded funds (ETFs) have emerged as efficient vehicles. Update: Top 10 Stocks and ETFs Poised to Outperform in October 2025 A set of leading semiconductor and AI ETFs competing with VanEck Semiconductor ETF (SMH) for 2025, along with key growth projections and features, is as follows: Top Semiconductor ETFs (Competitors to SMH) VanEck Semiconductor ETF (SMH) : The largest semiconductor ETF tracking the MVIS US Listed Semiconductor 25 Index, heavily weighted toward Nvidia (20%+), TSMC, and Broadcom. It offers concentrated exposure and has a 5-year annualized return of around 29.6%. Expense ratio: 0.35%. iShares Semiconductor ETF (SOXX) : Tracks the ICE Semiconductor...
Here are the top 10 ETF picks for September 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. We’ve ranked the 10 ETF picks for September 2025 based on their year-to-date (YTD) performance and Assets Under Management (AUM) as of September 2025, using available data from the provided references and general market insights. Since precise YTD performance and AUM figures for some ETFs (e.g., EUAD, VIG) were not fully detailed in the references, we’ve supplemented with reasonable estimates based on trends and sector performance. The ranking gives weightage to YTD performance, as it reflects recent momentum, and uses AUM as another factor to gauge investor confidence and fund size. Update: Top 10 ETF Picks for October 2025 Ranking Methodology YTD Performance: Based on reported or estim...
As we enter the latter half of 2025, the technology sector continues to dominate global markets, driven by breakthroughs in artificial intelligence (AI), semiconductors, robotics, and cloud computing. With the S&P 500's tech component accounting for over 34% of the index and the Nasdaq-100 even more heavily weighted toward innovation-driven companies, tech and innovation ETFs offer investors a streamlined way to capitalize on these trends. These exchange-traded funds (ETFs) provide diversified exposure to high-growth areas without the need to pick individual stocks, reducing some of the inherent risks while maintaining potential for substantial returns. Update: Top 10 Stocks and ETFs Poised to Outperform in October 2025 This comprehensive guide explores the current market landscape, key selection criteria for ETFs, top picks for 2025, portfolio-building strategies, associated risks, and forward-looking forecasts. Whether you're a beginner investor or a seasoned portfolio m...
With the Federal Reserve maintaining its rate-cutting trajectory into October 2025 amid heightened market volatility and sector rotation, opportunities are emerging in small caps, semiconductors/AI, value stocks, and gold miners as hedges. Based on recent analyses from Zacks, Morningstar, Yahoo Finance, and ETF experts, we've compiled a forward-looking list of 20 recommendations (10 stocks and 10 ETFs) expected to capitalize on these trends through the end of October and into Q4. Selections emphasize high-conviction picks with upward earnings revisions, undervaluation, and momentum in resilient sectors. Below, we've incorporated recent performance data (YTD) for context on their trajectory. Top 10 Stocks to Watch in October 2025 Drawing from recent expert analyses and market forecasts, these stocks are selected for their strong momentum, earnings potential, and sector tailwinds in areas like technology, commodities, consumer staples, and AI amid ongoing rate cuts and economic r...
Here are the top 10 pharmaceutical companies as of 2025, updated based on second quarter 2025 revenue data. AstraZeneca, Novartis and Vertex each posted 12% sales increases, offering more evidence of their upward trajectories in recent years. Credit: fiercepharma.com Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). Updates: Drug Stock Rally Helps Push Dow and S&P 500 to Records — WSJ ( Oct 2, 2025 ) Eli Lilly's (LLY) shares jumped 8.6% amid reports of a drug-pricing deal between the White House and the pharmaceutical industr...
Gold and silver ETFs have shown strong performance in 2025, surpassing the S&P 500 amid inflation concerns, geopolitical tensions, and central bank buying. This article updates the best-performing gold and silver ETFs based on recent data, including 1-year returns, assets under management (AUM), expense ratios, and key notes, evaluating their pros, cons, and attractiveness in the current market.The best gold and silver ETFs of 2025 are noted for exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Returns have adjusted slightly since late August due to recent price movements, but momentum remains strong with gold and silver near record highs. Here are the top options across global and key regional markets as of September 2025: Best Gold ETFs of 2025 VanEck Gold Miners ETF (GDX) YTD Performance: +80–115% (reported range for September 2025) ( TradingView ) AUM: ~$16.5B (estimated, based on historical size and 2025 inflows) Rationa...
Executive Summary As of September 2025, stablecoins have solidified their position as a cornerstone of the digital economy, with a global market capitalization exceeding $250-280 billion and transaction volumes on track to surpass $40 trillion annually—eclipsing traditional payment networks like Visa and Mastercard combined. These USD-pegged digital assets are no longer fringe elements of cryptocurrency but are driving real-world applications in payments, remittances, and institutional finance. Regulatory clarity, particularly through the U.S. GENIUS Act signed in July 2025, has accelerated institutional adoption, while emerging markets lead in relative usage. This report expands on the transformative potential of stablecoins, highlighting market growth, key regulatory updates, adoption drivers, leading companies, and forward-looking opportunities. While holding stablecoins offers stability rather than appreciation, the ecosystem's infrastructure providers present significant upsid...
The best artificial intelligence (AI) stocks to watch and potentially invest in for 2025 include a mix of well-established tech giants and high-growth specialized companies. Below is a brief overview of the state of AI, followed by a list of AI stocks that look promising for 2025. State Of Artificial Intelligence In 2025 A McKinsey report characterizes 2023 as the year "the world discovered generative AI (gen AI)." 2024 is when businesses began realizing value from using gen AI. The rising adoption has sparked extreme demand for AI-capable computing power. Data centers, in turn, invested billions in hardware and software for powering, developing and training AI applications. In 2025, companies like OpenAI will look to move AI's capabilities into increasingly complex tasks. Use cases for AI will expand across industries and into the personal computing space. Organizations that have invested in AI will attempt to quantify the business value of those investments....
Here are the top 10 ETF picks for October 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. We’ve ranked the 10 ETF picks for October 2025 based on their year-to-date (YTD) performance and Assets Under Management (AUM), using available data from the provided references and general market insights. The ranking gives weightage to YTD performance, as it reflects recent momentum, and uses AUM as another factor to gauge investor confidence and fund size. These ETFs target high-growth areas like gold mining, crypto, technology, and sustainable themes, based on top-performing indices and expert picks for Q4 momentum. These ETFs have delivered strong returns over recent months and 2025 year-to-date, spanning sectors like gold mining, uranium, defense, AI, and blockchain: Ranking Methodolo...
Comments